Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
You may also be interested in...
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.